Cross-source evidence timeline

Palopegteriparatide research timeline

Follow 16 selected, directly cited source records from August 9, 2024 through November 5, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.

16Selected records
3Source years
3Evidence lanes
November 5, 2026Latest source date

Source year

2026

12 records
  1. Clinical trials

    ClinicalTrials.gov record NCT07081997↗

    PeptideScanner retained ClinicalTrials.gov record NCT07081997 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was palopegteriparatide.↗

  2. Literature metadata

    Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults.↗

    PubMed lists PMID 42924498 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-23 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia.↗

    PubMed lists PMID 42871663 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Off-label palopegteriparatide for severe pediatric postsurgical hypocalcemia.↗

    PubMed lists PMID 42789535 in European journal of endocrinology as Journal Article, Case Reports, with publication-date metadata of 2026-10-05 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Literature metadata

    Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial.↗

    PubMed lists PMID 41636590 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Palopegteriparatide therapy for hypoparathyroidism: targeting the PTH receptor rouses the sleeping skeleton.↗

    PubMed lists PMID 42139093 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update.↗

    PubMed lists PMID 42614145 in JBMR plus as Case Reports, Journal Article, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism.↗

    PubMed lists PMID 42440695 in Journal of the Endocrine Society as Journal Article, with publication-date metadata of 2026-04-18 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT07264634↗

    PeptideScanner retained ClinicalTrials.gov record NCT07264634 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was palopegteriparatide.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT07706764↗

    PeptideScanner retained ClinicalTrials.gov record NCT07706764 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was palopegteriparatide.↗

  11. Regulatory

    Federal Register notice 2026-10277↗

    The Federal Register published notice 2026-10277, attributed to FDA and its parent HHS department, on 2026-05-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT07345494↗

    PeptideScanner retained ClinicalTrials.gov record NCT07345494 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was palopegteriparatide.↗

Source year

2025

3 records
  1. Literature metadata

    Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA).↗

    PubMed lists PMID 41134515 in Advances in therapy as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Regulatory

    Federal Register notice 2025-16269↗

    The Federal Register published notice 2025-16269, attributed to FDA and its parent HHS department, on 2025-08-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.↗

  3. Literature metadata

    Palopegteriparatide.↗

    PubMed lists PMID 39437769 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2025-01-06 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Source year

2024

1 record
  1. Regulatory

    Drugs@FDA application NDA216490↗

    The official Drugs@FDA dataset lists original submission 1 for NDA 216490 with status AP dated 2024-08-09, and names palopegteriparatide among the application record's active ingredients.↗